Science Explorer Back to mapMap
Discussion
Institution · ANZCHOG

Most cited papers from ANZCHOG

ANZCHOG

What are the most cited papers from ANZCHOG?

The most cited paper from ANZCHOG is "A treatment protocol for infants younger than 1 year with acute lymphoblastic leukaemia (Interfant-99): an observational study and a multicentre randomised trial" (Rob Pieters et al., 2007), with 661 citations. Next come "2010 Gynecologic Cancer InterGroup (GCIG) Consensus Statement on Clinical Trials in Ovarian Cancer" (430) and "The Fontan Procedure" (368).

Showing 50 of 64 papers. Every paper is listed.

Most cited papers, sortable by citations and release date
#Paper
1 A treatment protocol for infants younger than 1 year with acute lymphoblastic leukaemia (Interfant-99): an observational study and a multicentre randomised trial Rob Pieters et al. · The Lancet Jul 2007 661
2 2010 Gynecologic Cancer InterGroup (GCIG) Consensus Statement on Clinical Trials in Ovarian Cancer Gavin C.E. Stuart, Henry Charles Kitchener, Monica A. Bacon et al. · International Journal of Gynecological Cancer Open access Apr 2011 430
3 The Fontan Procedure Yves d’Udekem, Ajay J. Iyengar, Andrew Donald Cochrane et al. · Circulation Open access 10 Sep 2007 368
4 Outcome of Infants Younger Than 1 Year With Acute Lymphoblastic Leukemia Treated With the Interfant-06 Protocol: Results From an International Phase III Randomized Study Rob Pieters et al. · Journal of Clinical Oncology Open access 8 Jul 2019 305
5 Improved outcome with hematopoietic stem cell transplantation in a poor prognostic subgroup of infants with mixed-lineage-leukemia (MLL)–rearranged acute lymphoblastic leukemia: results from the Interfant-99 Study Georg Mann et al. · Blood Open access 30 Jun 2010 167
6 Multiomic neuropathology improves diagnostic accuracy in pediatric neuro-oncology Dominik Sturm et al. · Nature Medicine Open access 16 Mar 2023 146
7 Prognostic value of rare IKZF1 deletion in childhood B-cell precursor acute lymphoblastic leukemia: an international collaborative study Judith M. Boer et al. · Leukemia Open access 23 Jul 2015 107
8 Clinical Implications of Minimal Residual Disease Detection in Infants With KMT2A-Rearranged Acute Lymphoblastic Leukemia Treated on the Interfant-06 Protocol Janine Stutterheim et al. · Journal of Clinical Oncology Open access 6 Jan 2021 66
9 High prevalence of relapse in children with Philadelphia-like acute lymphoblastic leukemia despite risk-adapted treatment Susan L. Heatley et al. · Haematologica Open access 21 Sep 2017 62
10 Outcome of relapsed infant acute lymphoblastic leukemia treated on the interfant-99 protocol Emma M. C. Driessen et al. · Leukemia 15 Sep 2015 55
11 KMT2A rearranged acute lymphoblastic leukaemia: Unravelling the genomic complexity and heterogeneity of this high-risk disease Michelle O. Forgione, Barbara J. McClure, Laura N Eadie et al. · Cancer Letters 6 Nov 2019 50
12 Childhood cancer survivorship: barriers and preferences Christina Signorelli, Claire Elizabeth Wakefield, Jordana K. McLoone et al. · BMJ Supportive & Palliative Care Open access 11 Nov 2019 38
13 A phase I study of panobinostat in pediatric patients with refractory solid tumors, including CNS tumors Paul Wood, Robyn Strong, Grant A. McArthur et al. · Cancer Chemotherapy and Pharmacology 9 Jul 2018 37
14 JAK2 Alterations in Acute Lymphoblastic Leukemia: Molecular Insights for Superior Precision Medicine Strategies Charlotte E. J. Downes, Barbara J. McClure, Daniel P. McDougal et al. · Frontiers in Cell and Developmental Biology Open access 12 Jul 2022 36
15 DUX Hunting—Clinical Features and Diagnostic Challenges Associated with DUX4-Rearranged Leukaemia Jacqueline A. Rehn, Matthew J. O'Connor, Deborah L. White et al. · Cancers Open access 30 Sep 2020 30
16 Implementation of DNA Methylation Array Profiling in Pediatric Central Nervous System Tumors Christine L. White et al. · Journal of Molecular Diagnostics Open access 28 Jul 2023 24
17 Minimal residual disease and outcome characteristics in infant KMT2A-germline acute lymphoblastic leukaemia treated on the Interfant-06 protocol Janine Stutterheim et al. · European Journal of Cancer Open access 13 Nov 2021 24
18 Acquired JAK2 mutations confer resistance to JAK inhibitors in cell models of acute lymphoblastic leukemia Charlotte E. J. Downes, Barbara J. McClure, John B. Bruning et al. · npj Precision Oncology Open access 10 Aug 2021 24
19 RaScALL: Rapid (Ra) screening (Sc) of RNA-seq data for prognostically significant genomic alterations in acute lymphoblastic leukaemia (ALL) Jacqueline A. Rehn, Chelsea Mayoh, Susan L. Heatley et al. · PLoS Genetics Open access 17 Oct 2022 23
20 Multi-Cohort Transcriptomic Subtyping of B-Cell Acute Lymphoblastic Leukemia Ville‐Petteri Mäkinen, Jacqueline A. Rehn, James Breen et al. · International Journal of Molecular Sciences Open access 20 Apr 2022 23
21 MLLT10 rearranged acute leukemia: Incidence, prognosis, and possible therapeutic strategies Michelle O. Forgione, Barbara J. McClure, David T. O. Yeung et al. · Genes Chromosomes and Cancer 28 Jul 2020 22
22 HMGN1 plays a significant role in CRLF2 driven Down Syndrome leukemia and provides a potential therapeutic target in this high-risk cohort Elyse C. Page, Susan L. Heatley, Laura N Eadie et al. · Oncogene Open access 2 Dec 2021 21
23 Prospective audit of treatment of paediatric febrile neutropenia in Australasia JD Chamberlain, Elizabeth Smibert, Jane Skeen et al. · Journal of Paediatrics and Child Health Nov 2005 18
24 “How long will I continue to be normal?” Adults with a Fontan circulation's greatest concerns Karin du Plessis, Rebecca Peters, Ingrid King et al. · International Journal of Cardiology 3 Apr 2018 15
25 Two novel cases of NUTM1‐rearranged B‐cell acute lymphoblastic leukaemia presenting with high‐risk features Barbara J. McClure, Manika Pal, Susan L. Heatley et al. · British Journal of Haematology Open access 12 Dec 2021 13
26 Importance of radiation time and dose factors on outcome for childhood medulloblastoma* Michael Back, Verity Ahern, Megan Berry et al. · Australasian Radiology Open access 12 Jul 2005 12
27 Sustained Benefit of Blinatumomab in Infants With KMT2A -Rearranged ALL: Long-Term Outcomes, Toxicity, and Pharmacokinetics Miguel Vieira Martins, Paola De Lorenzo, Rishi Sury Kotecha et al. · Journal of Clinical Oncology Open access 8 Jan 2026 10
28 Clinical activity in general practice before sarcoma diagnosis: an Australian cohort study Meena Rafiq, Jasper de Boer, Jasmine Mar et al. · British Journal of General Practice Open access 25 Mar 2024 10
29 Enhanced Natural Killer and Cytotoxic T Lymphocyte Responses, with Decreased Monocytic Myeloid Derived Suppressor Cells May Promote Treatment Free Remission in Chronic Myeloid Leukaemia Patients Following Tyrosine Kinase Inhibitor Cessation Amy Lawrason Hughes, Jade Clarson, Deborah L. White et al. · Blood 2 Dec 2016 10
30 Synergistic Strategies for KMT2A-Rearranged Leukemias: Beyond Menin Inhibitor Sandra Cantilena, Mohamed Salem Alameri, Noélia Che et al. · Cancers Open access 29 Nov 2024 9
31 Gain of chromosome 21 increases the propensity for P2RY8::CRLF2 acute lymphoblastic leukemia via increased HMGN1 expression Elyse C. Page, Susan L. Heatley, Jacqueline A. Rehn et al. · Frontiers in Oncology Open access 6 Jul 2023 8
32 A multi-institutional retrospective pooled outcome analysis of molecularly annotated pediatric supratentorialZFTA-fused ependymoma Chia Huan Ng et al. · Neuro-Oncology Advances Open access 2023 8
33 High‐risk B‐cell acute lymphoblastic leukaemia presenting with hypereosinophilia and acquiring a novel PAX5 fusion on relapse Barbara J. McClure, Susan L. Heatley, Jacqueline A. Rehn et al. · British Journal of Haematology Open access 30 Jul 2020 8
34 Reproducible Bioinformatics Analysis Workflows for Detecting IGH Gene Fusions in B-Cell Acute Lymphoblastic Leukaemia Patients Ashlee J. Thomson, Jacqueline A. Rehn, Susan L. Heatley et al. · Cancers Open access 26 Sep 2023 7
35 Systems-Level Change to Alleviate Barriers to Cancer Clinical Trial Access for Adolescents and Young Adults in Australia Justine A. Ellis, Vajiranee S. Malalasekera, Christie Ann Allan et al. · Journal of Adolescent and Young Adult Oncology Open access 23 Jul 2021 7
36 Precision medicine approaches may be the future for CRLF2 rearranged Down Syndrome Acute Lymphoblastic Leukaemia patients Elyse C. Page, Susan L. Heatley, David T. O. Yeung et al. · Cancer Letters 4 Jun 2018 6
37 Activity of STAMP inhibitors in ABL2 rearranged acute lymphoblastic leukemia is dependent on the Abl2 SH3 domain Elias Lagonik, Elyse C. Page, John B. Bruning et al. · Blood Neoplasia Open access 25 Apr 2025 5
38 Identification of a novel GOLGA4–JAK2 fusion gene in B‐cell acute lymphoblastic leukaemia Charlotte E. J. Downes, Jacqueline A. Rehn, Susan L. Heatley et al. · British Journal of Haematology Open access 25 Oct 2021 5
39 Deciphering IGH rearrangement complexity and detection strategies in acute lymphoblastic leukaemia Ashlee J. Thomson, Jacqueline A. Rehn, David T. O. Yeung et al. · npj Precision Oncology Open access 4 Apr 2025 4
40 The acquisition order of leukemic drug resistance mutations is directed by the selective fitness associated with each resistance mechanism Benjamin Chia Sing Leow, Chung Hoow Kok, David T. O. Yeung et al. · Scientific Reports Open access 11 Aug 2023 4
41 In-vitromodeling of TKI resistance in the high-risk B-cell acute lymphoblastic leukemia fusion geneRANBP2-ABL1- implications for targeted therapy Susan L. Heatley, Kartini Asari, Caitlin E Schutz et al. · Leukemia & lymphoma/Leukemia and lymphoma 2 Jan 2021 4
42 Acquired Mutations within the JAK2 Kinase Domain Confer Resistance to JAK Inhibitors in an in Vitro model of a High-Risk Acute Lymphoblastic Leukemia Charlotte E. J. Downes, Barbara J. McClure, Jacqueline A. Rehn et al. · Blood 4 Nov 2020 4
43 Variations of Surveillance Practice for Patients with Bone Sarcoma: A Survey of Australian Sarcoma Clinicians Jeremy Howard Lewin, Kate Thompson, Susie Bae et al. · Sarcoma Open access 2017 4
44 Case Report: Precision Medicine Target Revealed by In Vitro Modeling of Relapsed, Refractory Acute Lymphoblastic Leukemia From a Child With Neurofibromatosis Susan L. Heatley, Elyse C. Page, Laura N Eadie et al. · Frontiers in Oncology Open access 20 Apr 2022 3
45 High Prevalence of Relapse in Australian Children with Ph-like Acute Lymphoblastic Leukemia Despite Risk Adapted Treatment Susan L. Heatley et al. · Blood 3 Dec 2015 3
46 “If you build it, they will come”: the convergence of funding, research and collaboration in paediatric brain cancer clinical trials Jordan R. Hansford, Santosh Valvi, Jasper de Boer et al. · The Medical Journal of Australia Open access 7 Nov 2024 2
47 Case Report: Rare IKZF1 Gene Fusions Identified in Neonate with Congenital KMT2A-Rearranged Acute Lymphoblastic Leukemia Laura N Eadie, Jacqueline A. Rehn, James Breen et al. · Genes Open access 19 Jan 2023 2
48 ATRT-17. A phase II study of continuous low dose panobinostat in paediatric patients with malignant rhabdoid tumours and atypical teratoid rhabdoid tumours. Paul Wood, Jayesh Desai, Kelly Waldeck et al. · Neuro-Oncology Open access Jun 2022 2
49 Acute Leukemia of Ambiguous Lineage: A Comprehensive Survival Analysis Enables Designing New Treatment Strategies Ondřej Hrušák et al. · Blood 2 Dec 2016 2
50 Identification of a Novel, Oncogenic and Targetable TPR::ABL2 Fusion Gene in T‐Cell Acute Lymphoblastic Leukaemia Elias Lagonik, Elyse C. Page, Laura N Eadie et al. · eJHaem Open access 2 Mar 2026 1

Citations are OpenAlex's own counts, from its 2026-09-23 snapshot, so the ranking can differ from Google Scholar or Web of Science. A paper is listed for an institution when any of its authors gave it as an affiliation; retracted papers and papers whose citation count cannot be traced to citing works are left out, and a preprint and the article it became are shown once. Release dates are OpenAlex's: where a source gave only a month or a year, that is what is shown. How the lists are chosen.